Takeda (NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, approved as replacement therapy for people two years of age and older with primary immunodeficiency (PI).
GAMMAGARD LIQUID ERC is a liquid immunoglobulin therapy that does not require reconstitution and has a low immunoglobulin A (IgA) content less than or equal to 2 µg/mL in a 10% solution to be administered intravenously or subcutaneously.1
“As the latest addition to our broad IG portfolio, GAMMAGARD LIQUID ERC underscores our ongoing dedication to providing differentiated therapeutic options to meet the varied needs of people with primary immunodeficiency, including those who require an option with low IgA content,” said Uthra Sundaram, senior vice president and head of Takeda’s U.S. Plasma-Derived Therapies Business Unit.
“As a ready-to-use liquid, GAMMAGARD LIQUID ERC does not require reconstitution and can be administered intravenously or subcutaneously which may help ease the administration burden for patients and their health care providers.”
GAMMAGARD LIQUID ERC shares the same state-of-the-art manufacturing process as the other liquid formulations in the Takeda IG portfolio, and features an Enhanced Removal Capability (ERC) to reduce the IgA content.
TAK shares knocked off 10 cents to $15.98.
